Claims
- 1. A steroidal glycoside compound of Formula I ##STR10## and the pharmaceutically-acceptable salts and hydrates thereof wherein: R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen, hydroxy, halo, amino, azido, (C.sub.1 -C.sub.6)alkoxy(C.sub.1 -C.sub.6)alkoxy or --Z--R.sup.5 ;
- Z for each occurrence is independently selected from the group consisting of --NH--C(.dbd.O)--, --O--C(.dbd.O)--, --O--C(.dbd.O)--N(R.sup.6)--, --NH--C(.dbd.O)--N(R.sup.6)--, --O--C(.dbd.S)--N(R.sup.6)-- and --O--C(.dbd.O)--N--(R.sup.6)--; ##STR11## wherein: - - - - - - is optionally a double bond;
- Q.sup.2 is --C(.dbd.O)--, --CH.sub.2 --, --C(N.dbd.OR.sup.9)-- or --CH(CH(CH.sub.3)--CH.sub.2 --CH.sub.2 --C(.dbd.O)(OR.sup.9))--; ##STR12## Q.sup.3 is --C(.dbd.O)--, --CH.sub.2 -- or Q.sup.4 is --CH.sub.2 -- or --C(.dbd.O)--; and
- Q.sup.5 is --CH.sub.2 -- or --C(.dbd.O)--;
- R.sup.5 for each occurrence is independently aryl, aryl(C.sub.1 -C.sub.6)alkyl, (C.sub.2 -C.sub.4)alkenyl, (C.sub.1 -C.sub.6)alkyl, (C.sub.3 -C.sub.7)cycloalkyl or (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.6)alkyl, and each R.sup.5 may be optionally mono-, di, or tri-substituted independently with halo, (C.sub.1 -C.sub.4)alkyl, hydroxy, phenoxy, trifluoromethyl, nitro, (C.sub.1 -C.sub.4)alkoxy, methylenedioxy, oxo, (C.sub.1 -C.sub.4)alkylsulfanyl, (C.sub.1 -C.sub.4)alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl, dimethylamino, mono- or di-(C.sub.1 -C.sub.4)alkylaminocarbonyl, (C.sub.1 -C.sub.4)alkylcarbonyl, (C.sub.1 -C.sub.4)alkoxycarbonyl or pyrrolidinylcarbonyl;
- R.sup.6 for each occurrence is independently hydrogen or (C.sub.1 -C.sub.4)alkyl, or R.sup.6 is taken together with the nitrogen to which it is attached and with R.sup.5, wherein R.sup.5 is a covalent bond, to form pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl, and such cyclic group may be mono-substituted on a carbon atom with (C.sub.1 -C.sub.4)alkoxycarbonyl;
- R.sup.9 is (C.sub.1 -C.sub.4)alkyl or aryl(C.sub.1 -C.sub.6)alkyl;
- m is 2, 3 or 4;
- wherein aryl is carbon-linked and is phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl or pyridyl;
- provided that where Q.sup.2 is --C(.dbd.N--OR.sup.9)--, Q.sup.3 is not --C(.dbd.O)--.
- 2. A compound according to claim 1 wherein the C.sup.3 oxy is beta, and the C.sup.5 hydrogen is alpha.
- 3. A compound according to claim 2 wherein the C.sup.1' and C.sup.1" anomeric oxy are beta, and R.sup.3 is alpha.
- 4. A compound according to claim 3 wherein R.sup.1 is hydroxy, R.sup.2 and R.sup.3 are each independently Z--R.sup.5 where Z is --O--(C.dbd.O)--N(R.sup.6)-- and R.sup.6 is hydrogen.
- 5. A method of treating hypercholesterolemia which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 6. A method of treating atherosclerosis which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.
- 7. A pharmaceutical composition for the treatment of hypercholesterolemia or atherosclerosis in a mammal which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
CROSS REFERENCE TO RELATED APPLICATION
This application is the national stage of International Application No. PCT/IB95/00409 having an international filing date of May 29, 1995.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/IB95/00409 |
5/29/1995 |
|
|
11/21/1997 |
11/21/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/38466 |
12/5/1996 |
|
|
US Referenced Citations (7)
Foreign Referenced Citations (1)
Number |
Date |
Country |
9307167 |
Apr 1993 |
WOX |